Candriam SCA’s Centessa Pharmaceuticals CNTA Stock Holding History

Candriam SCA’s Portfolio CNTA Stock Details CNTA Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	–	Sell	-36,254	Closed	-$1.44M	–	688
2026 Q1	$1.44M	Sell	36,254 -359,369	-91%	-$9.19M	0.01%	569
2025 Q4	$9.89M	Buy	395,623 +52,416	+15%	+$1.33M	0.05%	270
2025 Q3	$8.32M	Sell	343,207 -4,392	-1%	-$78.1K	0.04%	298
2025 Q2	$4.57M	Buy	+347,599	New	+$4.4M	0.03%	368

Candriam SCA's CNTA Position: Q2 2026 in Review

Candriam SCA sold out of Centessa Pharmaceuticals (CNTA) in Q2 2026, closing a stake of 36,254 shares — an estimated $1.44M sold.

Candriam SCA first reported a position in CNTA in Q2 2025 and held it in 4 quarters. The position peaked at $9.89M in Q4 2025. 0 funds tracked by Wall St. Rank hold CNTA as of Q2 2026.

Candriam SCA reported no remaining Centessa Pharmaceuticals position as of Q2 2026 after selling out during the quarter.
Candriam SCA sold 36,254 Centessa Pharmaceuticals shares in Q2 2026, an estimated $1.44M.
Candriam SCA first reported a position in Centessa Pharmaceuticals in Q2 2025 and held it in 4 quarters.
Candriam SCA's Centessa Pharmaceuticals position peaked at $9.89M in Q4 2025.
0 funds tracked by Wall St. Rank held Centessa Pharmaceuticals as of Q2 2026.

Based on Candriam SCA's 13F filing for Q2 2026, filed 13 Aug 2026.